# Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

> **NCT00362232** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 3148 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Enoxaparin
- **DRUG:** Placebo: tablet of Rivaroxaban
- **DRUG:** Placebo: syringes of Enoxaparin

## Key facts

- **NCT ID:** NCT00362232
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-01
- **Final completion:** 2008-01
- **Target enrollment:** 3148 (ACTUAL)
- **Last updated:** 2014-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362232, "Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00362232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*